JonesResearch analyst Debanjana Chatterjee initiated coverage of Tvardi Therapeutics (TVRD) with a Buy rating and $39 price target The company’s lead drug TTI-101 is being tested in Phase 2 REVERT studies for idiopathic pulmonary fibrosis and hepatocellular carcinoma, the analyst tells investors in a research note. The firm believes Tvardi “appears to be under the radar” and sees a favorable risk/reward into the second half of 2025 data.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue